Gates Ellen J, Bernath Anna K, Klegeris Andis
Department of Biology, University of British Columbia Okanagan Campus, Kelowna V1V 1V7, BC, Canada.
Rev Neurosci. 2022 Mar 21;33(7):767-787. doi: 10.1515/revneuro-2021-0146. Print 2022 Oct 26.
The global prevalence of Alzheimer's disease and Parkinson's disease is steadily increasing due to the aging population. The lack of effective drugs against these neurodegenerative disorders makes it imperative to identify new strategies for their prevention and treatment. Recent studies have revealed that harnessing the power of the gut microbiota through modification of diet may be a valuable approach for reducing the risk, modulating the symptoms, and ameliorating the pathophysiological aspects of neurodegenerative diseases. Consuming specific dietary components can alter the prevalence of bacterial communities within the gut to a healthy enterotype, which can influence the production of beneficial metabolites by microbiota. This article focuses on several dietary components, which have been demonstrated to affect the gut microbiota-brain axis and therefore could lead to attenuation of specific pathological processes in neurodegenerative diseases. Published evidence indicates that fermented foods, including kefir, and foods that are high in bioactive polyphenols and complex carbohydrates, such as grapes, pomegranates, and seaweed, may be effective at reducing neuroinflammation, oxidative stress, neurotransmitter dysfunction, and neuronal death associated with Alzheimer's and Parkinson's diseases. Even though experimental evidence supporting the protective properties of the above dietary components in these diseases is emerging, it is evident that further human clinical studies are required to conclusively establish the benefits of any suggested dietary interventions. The translational potential of such research is illustrated by the clinical success of the recently developed Alzheimer's drug, GV-971, which is a seaweed derivative that works by modulating the gut microbiota-brain axis.
由于人口老龄化,全球阿尔茨海默病和帕金森病的患病率正在稳步上升。缺乏针对这些神经退行性疾病的有效药物使得确定其预防和治疗的新策略变得势在必行。最近的研究表明,通过饮食调整来利用肠道微生物群的力量可能是降低神经退行性疾病风险、调节症状和改善病理生理方面的一种有价值的方法。食用特定的饮食成分可以将肠道内细菌群落的患病率改变为健康的肠型,这可以影响微生物群产生有益代谢物。本文重点介绍了几种饮食成分,这些成分已被证明会影响肠道微生物群-脑轴,因此可能导致神经退行性疾病中特定病理过程的减轻。已发表的证据表明,发酵食品,包括开菲尔,以及富含生物活性多酚和复合碳水化合物的食物,如葡萄、石榴和海藻,可能有助于减轻与阿尔茨海默病和帕金森病相关的神经炎症、氧化应激、神经递质功能障碍和神经元死亡。尽管支持上述饮食成分对这些疾病具有保护作用的实验证据正在出现,但显然还需要进一步的人体临床研究来最终确定任何建议的饮食干预措施的益处。最近开发的阿尔茨海默病药物GV-971的临床成功说明了此类研究的转化潜力,GV-971是一种海藻衍生物,通过调节肠道微生物群-脑轴发挥作用。